Patisiran update from Alnylam | ABUS Message Board Posts

Arbutus Biopharma

  ABUS website

ABUS   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  34810 of 34823  at  5/24/2020 12:12:01 PM  by

The Rooster

The following message was updated on 5/24/2020 12:12:48 PM.

Patisiran update from Alnylam

  
Marked reduction in fatalities and improvement in quality life in FAP patients who took patisiran:
 
 

Alnylam Presents New Long-Term Results from Global Open-Label Extension Study of ONPATTRO® (patisiran) at the European Academy of Neurology Virtual Congress 2020

 

May 22, 2020

Patisiran Continues to Demonstrate Reversal of Neuropathy Progression, Improvement in Quality of Life, and Consistent Safety Profile with Additional 24 Months of Treatment in Global Open-Label Extension (OLE) Study

Interim Data Presented on Patisiran Treatment in Patients with Disease Progression After an Orthotopic Liver Transplant

 
 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 179
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...